Healthcare Resource Utilization and Costs Associated With Infectious Mononucleosis in the United States

Author(s)

Georgieva M1, Wang J1, Lu T1, Hall S1, Diaz-Decaro J1, Kunzweiler C1, Buck P2
1Moderna, Inc., Cambridge, MA, USA, 2Moderna, Inc., Philadelphia, PA, USA

OBJECTIVES: Epstein-Barr virus (EBV) is a common herpes virus that infects most people during their lifetime. EBV causes over 90% of infectious mononucleosis (IM) cases which can result in prolonged symptoms, such as fever and swollen lymph nodes, as well as hospitalization. We examined healthcare resource utilization (HCRU) and costs attributable to IM in US claims data.

METHODS: Utilizing the Merative™ MarketScan® Commercial Claims and Encounters and Medicaid databases during the pre-COVID-19 pandemic period (June 2017-February 2020), individuals aged 5-40 years with IM diagnosis (ICD-10: B27.0x, B27.8x, B27.9x) were selected for the IM cohort (first diagnosis=index date). Controls (no IM diagnosis at any point) were matched 1:1 on a healthcare visit date (same as the index date for the case ±7 days) as well as demographics and comorbidities at baseline. Individuals with any transplant diagnosis were excluded. Individuals were required to have ≥6 months of continuous enrollment pre-index (baseline) and post-index (follow-up). All-cause HCRU and total direct costs (in 2022 USD) were summarized over a 6-month follow-up period.

RESULTS: 22,906 Commercially-insured and 8,197 Medicaid-enrolled matched pairs were included. Among Commercial pairs, the mean (SD) age at index date was 18(±6) years and 57% were female. Among Medicaid pairs, the mean age was 14(±6) years and 61% were female. During the 6-month follow-up, IM cases had a higher median number of total HCRU visits compared with controls (Commercial: 5.0 [IQR: 3.0-8.0]) vs. 3.0 [2.0-7.0]; Medicaid: 6.0 [4.0-11.0] vs. 5.0 [2.0-10.0], all p<0.001). Median total costs (medical+pharmacy) were $1,333 [IQR: $541-$3,424] for Commercial cases (vs. $841 [$346-$2,281] for controls) and $897 [$381-$1,995] for Medicaid cases (vs. $577 [$237-$1,428] for controls, all p<0.001).

CONCLUSIONS: Individuals diagnosed with IM in the US had higher HCRU and costs during the 6-month follow-up than non-IM controls. IM prevention via EBV vaccination may have a positive impact on healthcare resource use.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

EE795

Topic

Economic Evaluation, Epidemiology & Public Health, Study Approaches

Topic Subcategory

Public Health

Disease

Infectious Disease (non-vaccine), Vaccines

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×